Journal article · 2026 · Open access

Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial

Sreya Duttagupta, Meriem Messaoudene, Sebastian Hunter, Antoine Desîlets, Rahima Jamal, Catalin Liviu Dragos Mihalcioiu, Wiam Belkaïd, Nicolas Marcoux, Marine Fidelle, Déborah Suissa, Mayra Ponce, Mallia Geiger and 37 more

Nature Medicine, 32(4), 1337–1350 · Published 28 January 2026 · DOI 10.1038/s41591-025-04186-5

Open PDFView at the publisherCite this paper

In brief

“Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial” is a 2026 journal article by Sreya Duttagupta and 48 co-authors, published in Nature Medicine. OpenAlex counts 121 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.

Citations
121
Most cited in
2026 (120)
Field-weighted impact
280.40
References
68
Authors
49

Abstract

Immune checkpoint inhibitors (ICI) have improved outcomes for patients with non-small cell lung cancer (NSCLC) and melanoma, yet over half of patients exhibit primary resistance. Fecal microbiota transplantation (FMT) may overcome resistance to anti-programmed cell death protein 1 (PD-1) therapy. The clinical activity and safety of FMT plus anti-PD-1 in NSCLC or anti-PD-1 plus anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma have not been evaluated. Here we report results from FMT-LUMINate, a multicenter, open-label, phase 2 trial assessing healthy donor FMT plus anti-PD-1 in NSCLC (n = 20) or anti-PD-1 plus anti-CTLA-4 (dual ICI) in melanoma (n = 20), in the first-line setting. Eligible patients received a single FMT via oral capsules prior to ICI initiation. The primary endpoint was objective response rate (ORR) in NSCLC. Secondary endpoints included ORR in melanoma, safety and donor-host microbiome similarity. In NSCLC, the ORR was 80% (16/20), meeting the study primary endpoint. In melanoma, the ORR was 75% (15/20). FMT was deemed safe in both cohorts by an independent data and safety monitoring committee, with no grade 3 or higher adverse events (AEs) in NSCLC and 13 (65%) patients experiencing grade 3 or higher AEs in melanoma. Shotgun metagenomic sequencing revealed that responders developed a distinct post-FMT gut microbiome composition, independent of acquired donor-recipient similarity or strain-level engraftment. Responders exhibited significantly greater loss of baseline bacterial species compared to non-responders, with frequent depletion of Enterocloster citroniae, E. lavalensis and Clostridium innocuum. This finding was reproduced across three published FMT oncology trials. We recolonized antibiotic-treated, tumor-bearing mice with post-FMT stool from two responder patients, and reintroduction of the specific bacterial species that were lost after FMT abrogated the antitumor effect of ICI. Taken together, these findings confirm the clinical activity of FMT in combination with ICI and suggest that the elimination of deleterious taxa is required for FMT-mediated therapeutic benefit. ClinicalTrials.gov identifier: NCT04951583 .

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., Ponce, M., Geiger, M., Malo, J., Piccinno, G., Punčochář, M., Filin, A., Heidrich, V., Rusu, D., Mbaye, B., . . . Elkrief, A. (2026). Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nature Medicine, 32(4), 1337–1350. https://doi.org/10.1038/s41591-025-04186-5

MLA 9

Duttagupta, Sreya, et al. “Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.” Nature Medicine, vol. 32, no. 4, 2026, pp. 1337–1350. https://doi.org/10.1038/s41591-025-04186-5.

Chicago

Duttagupta, Sreya, Meriem Messaoudene, Sebastian Hunter, Antoine Desîlets, Rahima Jamal, Catalin Liviu Dragos Mihalcioiu, Wiam Belkaïd, et al. 2026. “Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.” Nature Medicine 32 (4): 1337–1350. https://doi.org/10.1038/s41591-025-04186-5.

Harvard

Duttagupta, S. et al. (2026) ‘Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial’, Nature Medicine, 32(4), pp. 1337–1350. doi:10.1038/s41591-025-04186-5.

IEEE

S. Duttagupta et al., “Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial,” Nature Medicine, vol. 32, no. 4, pp. 1337–1350, 2026, doi: 10.1038/s41591-025-04186-5.

BibTeX

@article{duttagupta2026fecal,
  title     = {{Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial}},
  author    = {Duttagupta, Sreya and Messaoudene, Meriem and Hunter, Sebastian and Desîlets, Antoine and Jamal, Rahima and Mihalcioiu, Catalin Liviu Dragos and Belkaïd, Wiam and Marcoux, Nicolas and Fidelle, Marine and Suissa, Déborah and Ponce, Mayra and Geiger, Mallia and Malo, Julie and Piccinno, Gianmarco and Punčochář, Michal and Filin, Alysé and Heidrich, Vitor and Rusu, Diana and Mbaye, Babacar and Durand, Sylvère and Aissa, Imen Ben and Puller, Vadim and de Lahondès, Raynald and Blais, Normand and Tehfe, Mustapha Ali and Owen, Scott Peter and Bélanger, Karl and Parvathy, Seema Nair and Shieh, Benjamin and Raphael, Jacques and others},
  journal   = {Nature Medicine},
  year      = {2026},
  volume    = {32},
  number    = {4},
  pages     = {1337--1350},
  doi       = {10.1038/s41591-025-04186-5},
  url       = {https://doi.org/10.1038/s41591-025-04186-5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers

  • fecal microbiota transplantation
  • immune checkpoint inhibitors
  • non-small cell lung cancer
  • melanoma
  • anti-PD-1 therapy
  • CTLA-4 blockade
  • dual immune checkpoint blockade
  • primary resistance

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Duttagupta, S., Messaoudene, M., Hunter, S., Desîlets, A., Jamal, R., Mihalcioiu, C. L. D., Belkaïd, W., Marcoux, N., Fidelle, M., Suissa, D., Ponce, M., Geiger, M., Malo, J., Piccinno, G., Punčochář, M., Filin, A., Heidrich, V., Rusu, D., Mbaye, B., . . . Elkrief, A. (2026). Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nature Medicine, 32(4), 1337–1350. https://doi.org/10.1038/s41591-025-04186-5

How many times has this paper been cited?

121 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Sreya Duttagupta, Meriem Messaoudene, Sebastian Hunter, Antoine Desîlets, Rahima Jamal, Catalin Liviu Dragos Mihalcioiu, Wiam Belkaïd, Nicolas Marcoux, Marine Fidelle, Déborah Suissa, Mayra Ponce, Mallia Geiger and 37 more.

What is the DOI of this paper?

10.1038/s41591-025-04186-5, permanently at https://doi.org/10.1038/s41591-025-04186-5. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.